Crux Wealth Advisors Buys 1,375 Shares of IQVIA Holdings Inc. $IQV

Crux Wealth Advisors increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.9% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,644 shares of the medical research company’s stock after purchasing an additional 1,375 shares during the period. Crux Wealth Advisors’ holdings in IQVIA were worth $1,205,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after buying an additional 312,807 shares during the period. JPMorgan Chase & Co. increased its position in IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares during the last quarter. Nordea Investment Management AB lifted its holdings in IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares during the period. American Century Companies Inc. grew its stake in shares of IQVIA by 26.8% during the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after purchasing an additional 304,258 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of IQVIA by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock valued at $251,852,000 after purchasing an additional 40,699 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Down 0.6%

Shares of IQVIA stock opened at $204.51 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a fifty day moving average of $191.41 and a 200 day moving average of $169.19. The company has a market capitalization of $34.77 billion, a P/E ratio of 29.60, a P/E/G ratio of 2.25 and a beta of 1.32. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.21.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the business earned $2.64 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research reports. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Truist Financial lifted their price target on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. UBS Group raised their target price on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Finally, William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $234.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.